The public COA is shown in English and kept in its original laboratory form. Internal self-inspection COAs are private.
Muscle growth & growth hormone
Ipamorelin research material is available in 5mg, 10mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Ipamorelin research material is available in 5mg, 10mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
LYSENTA research catalogue
Description
Ipamorelin research material is available in 5mg, 10mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Supplied strictly as laboratory research material. Record the selected SKU, batch and COA in the research workflow.
Frequently asked questions
The displayed price is per vial. The spreadsheet box price has been divided by 10 without changing its total: selecting 10 vials equals one full box.
The minimum is 10 vials, and every additional quantity must be a multiple of 10.
When available, the public English COA is linked to the selected specification. Internal self-inspection COAs remain private in the administration area.
This material is supplied strictly for laboratory and research use and is not intended for human or animal use.
RESEARCH & QUALITY DOCUMENTATION
Content updated · English reference edition
Ipamorelin is a peptide investigated as a growth hormone secretagogue. Its pharmacology is a distinct subject from research on GHRH analogues, even though both may be discussed in relation to growth-hormone release. This page links catalogue specifications to an original pharmacology reference and explains why material identity and experimental context should be checked separately.
Original experimental pharmacology study
Raun and colleagues described ipamorelin's development and pharmacology in the European Journal of Endocrinology in 1998. The work provides a starting reference for its secretagogue activity and selectivity in the studied systems. Selectivity in a pharmacology experiment is not a guarantee of safety in people, and the paper does not validate a commercial research batch or a combined-peptide product.
Reference: Raun et al., 1998 — original ipamorelin pharmacology study ↗
Separate single-compound ipamorelin from products combined with CJC-1295 or tesamorelin. Research involving individual compounds does not automatically establish the properties of a mixture. Confirm the composition, component amounts and exact identity of any comparator before interpreting a comparison.
For an ipamorelin research purchase, first select the required specification and check its SKU. Review the associated public COA when available, then confirm the supplied lot with support. Where multiple compounds are present, ask how each component is identified; a general purity percentage should not be assumed to characterize every ingredient.
No. Selectivity describes a response under particular experimental conditions. It is not a general safety guarantee or an authorization to use a research material in people.
No. They are distinct compounds with different pharmacological research contexts. Use the exact material required by the study rather than treating related product categories as equivalents.
Not automatically. Findings about a single compound do not establish the identity, analytical quality or biological effects of a blend.
Sources describe the materials and conditions studied by their authors. They are not endorsements of LYSENTA or certificates for the products on this website.
Related does not mean interchangeable. Check composition and evidence separately.
Browse all research and documentation guides →
For laboratory research only. Not for human or animal use. No clinical dosing, treatment or administration advice is provided.
SAME CATEGORY
